{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:50:32Z","timestamp":1753181432372},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T00:00:00Z","timestamp":1261094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1038\/eye.2009.307","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T13:30:59Z","timestamp":1261143059000},"page":"1234-1242","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of fixed combinations of latanoprost\/timolol and dorzolamide\/timolol in open-angle glaucoma or ocular hypertension"],"prefix":"10.1038","volume":"24","author":[{"name":"for the Xalacom\/Cosopt European Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Miglior","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J W","family":"Grunden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,12,18]]},"reference":[{"key":"BFeye2009307_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487\u2013497.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2009307_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701\u2013713.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2009307_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/00061198-199902000-00007","volume":"8","author":"MG Bucci","year":"1999","unstructured":"Bucci MG . Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group. J Glaucoma 1999; 8: 24\u201330.","journal-title":"J Glaucoma"},{"key":"BFeye2009307_CR4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0002-9394(00)00717-0","volume":"130","author":"S Choudhri","year":"2000","unstructured":"Choudhri S, Wand M, Shields MB . A comparison of dorzolamide\u2013timolol combination versus the concomitant drugs. Am J Ophthalmol 2000; 130: 832\u2013833.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2009307_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1177\/112067210601600606","volume":"16","author":"G Holl\u00f3","year":"2006","unstructured":"Holl\u00f3 G, Chiselita D, Petkova N, Cvenkel B, Liehneova I, Izgi B et al. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006; 16: 816\u2013823.","journal-title":"Eur J Ophthalmol"},{"key":"BFeye2009307_CR6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/bjo.87.5.592","volume":"87","author":"A Hommer","year":"2003","unstructured":"Hommer A, Kapik B, Shams N, The Unoprostone Adjunctive Therapy Study Group. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide. Br J Ophthalmol 2003; 87: 592\u2013598.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2009307_CR7","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0161-6420(96)30509-5","volume":"103","author":"ER Strahlman","year":"1996","unstructured":"Strahlman ER, Vogel R, Tipping R, Clineschmidt CM . The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group. Ophthalmology 1996; 103: 1283\u20131293.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR8","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/00061198-200012000-00007","volume":"9","author":"RF Wang","year":"2000","unstructured":"Wang RF, Serle JB, Gagliuso DJ, Podos SM . Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes. J Glaucoma 2000; 9: 458\u2013462.","journal-title":"J Glaucoma"},{"key":"BFeye2009307_CR9","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","volume":"102","author":"A Alm","year":"1995","unstructured":"Alm A, Stjernschantz J . Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995; 102: 1743\u20131752.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR10","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1016\/S0161-6420(96)30407-7","volume":"103","author":"CB Camras","year":"1996","unstructured":"Camras CB, Alm A, Watson P, Stjernschantz J . Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 1996; 103: 1916\u20131924.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","volume":"103","author":"CB Camras","year":"1996","unstructured":"Camras CB . Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996; 103: 138\u2013147.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR12","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","volume":"135","author":"RK Parrish","year":"2003","unstructured":"Parrish RK, Palmberg P, Sheu WP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688\u2013703.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2009307_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0161-6420(96)30750-1","volume":"103","author":"P Watson","year":"1996","unstructured":"Watson P, Stjernschantz J . A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996; 103: 126\u2013137.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/S0161-6420(93)31484-3","volume":"100","author":"CB Toris","year":"1993","unstructured":"Toris CB, Camras CB, Yablonski ME . Effects of PhXA41, a new prostaglandin F2\u03b1 analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993; 100: 1297\u20131304.","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"BFeye2009307_CR15","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/S0039-6257(02)00306-5","volume":"47","author":"RN Weinreb","year":"2002","unstructured":"Weinreb RN, Toris CB, Gabelt BT, Lindey JD, Kaufman PL . Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002; 47 (Suppl 1): S53\u2013S64.","journal-title":"Surv Ophthalmol"},{"key":"BFeye2009307_CR16","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1001\/archopht.1993.01090100059027","volume":"111","author":"N Ziai","year":"1993","unstructured":"Ziai N, Dolan JW, Kacere RD, Brubaker RF . The effects on aqueous dynamics of PhXA41, a new prostaglandin F2\u03b1 analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993; 111: 1351\u20131358.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2009307_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/bjo.79.1.12","volume":"79","author":"A Alm","year":"1995","unstructured":"Alm A, Wideng\u00e5rd I, Kjellgren D, S\u00f6derstr\u00f6m M, Fristr\u00f6m B, Heijl A et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995; 79: 12\u201316.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2009307_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0161-6420(91)32173-0","volume":"98","author":"PY Lee","year":"1991","unstructured":"Lee PY, Shao H, Camras CB, Podos SM . Additivity of prostaglandin F2 alpha-1-isopropyl ester to timolol in glaucoma patients. Ophthalmology 1991; 98: 1079\u20131082.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR19","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1136\/bjo.78.12.899","volume":"78","author":"AH Rulo","year":"1994","unstructured":"Rulo AH, Greve EL, Hoyng PF . Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994; 78: 899\u2013902.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2009307_CR20","unstructured":"European Glaucoma Society. Terminology and Guidelines for Glaucoma, 3rd edn. DOGMA, Srl: Savona, Italy, 2008."},{"key":"BFeye2009307_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2105\/AJPH.83.5.711","volume":"83","author":"JH Gurwitz","year":"1993","unstructured":"Gurwitz JH, Glynn RJ, Monane M, Everitt DE, Gilden D, Smith N et al. Treatment for glaucoma: adherence by the elderly. Am J Public Health 1993; 83: 711\u2013716.","journal-title":"Am J Public Health"},{"key":"BFeye2009307_CR22","first-page":"233","volume":"26","author":"SC Patel","year":"1995","unstructured":"Patel SC, Spaeth GL . Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995; 26: 233\u2013236.","journal-title":"Ophthalmic Surg"},{"key":"BFeye2009307_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","volume":"144","author":"AL Robin","year":"2007","unstructured":"Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS . Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144: 533\u2013540.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2009307_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, Schundt DG, Pichert JW . Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003; 12: 393\u2013398.","journal-title":"J Glaucoma"},{"key":"BFeye2009307_CR25","unstructured":"Latanoprost\/Timolol Fixed Combination Investigator's Brochure (Pfizer internal document, New York, NY). June 2004, p 100."},{"key":"BFeye2009307_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0002-9394(02)01460-5","volume":"133","author":"AG Konstas","year":"2002","unstructured":"Konstas AG, Nakos E, Tersis I, Lallos NA, Leech JN, Stewart WC . A comparison of once-daily morning vs evening dosing of concomitant latanoprost\/timolol. Am J Ophthalmol 2002; 133: 753\u2013757.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2009307_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1001\/archopht.1997.01100160538002","volume":"115","author":"L Wayman","year":"1997","unstructured":"Wayman L, Larsson LI, Maus T, Brubaker R . Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol 1997; 115: 1368\u20131371.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2009307_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9394(99)00073-2","volume":"128","author":"AG Konstas","year":"1999","unstructured":"Konstas AG, Maltezos AC, Gandi S, Hudgins AC, Stewart WC . Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 1999; 128: 15\u201320.","journal-title":"Am J Ophthalmol"},{"key":"BFeye2009307_CR29","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1136\/bjo.2008.145219","volume":"92","author":"AGP Konstas","year":"2008","unstructured":"Konstas AGP, Mikropoulos D, Dimopoulos AT, Moumtzis G, Nelson LA, Stewart WC . Second-line therapy with dorzolamide\/timolol or latanoprost\/timolol fixed combination versus adding dorzolamide\/timolol fixed combination to latanoprost monotherapy. Br J Ophthalmol 2008; 92: 1498\u20131502.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2009307_CR30","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.1742-1241.2006.01126.x","volume":"61","author":"A Martinez","year":"2007","unstructured":"Martinez A, Sanchez M . Retrobulbar haemodynamic effects of the latanoprost\/timolol and the dorzolamide\/timolol fixed combinations in newly diagnosed glaucoma patients. Int J Clin Prac 2007; 61: 815\u2013825.","journal-title":"Int J Clin Prac"},{"key":"BFeye2009307_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ophtha.2003.05.019","volume":"111","author":"DH Shin","year":"2004","unstructured":"Shin DH, Feldman RM, Sheu WP, Fixed Combination Latanoprost\/Timolol Study Group. Efficacy and safety of the fixed combinations latanoprost\/timolol versus dorzolamide\/timolol in patients with elevated intraocular pressure. Ophthalmology 2004; 111: 276\u2013282.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR32","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/sj.eye.6701446","volume":"18","author":"AG Konstas","year":"2004","unstructured":"Konstas AG, Kozobolis VP, Lallos N, Christodoulakis E, Stewart JA, Stewart WC . Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%\/timolol maleate 0.5% and dorzolamide 2%\/timolol maleate 0.5%. Eye 2004; 18: 1264\u20131269.","journal-title":"Eye"},{"key":"BFeye2009307_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1136\/bjo.2003.029330","volume":"88","author":"J Garcia-Sanchez","year":"2004","unstructured":"Garcia-Sanchez J, Rouland JF, Spiegel D, Pajic B, Cunliffe I, Traverso C et al. A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe. Br J Ophthalmol 2004; 88: 877\u2013883.","journal-title":"Br J Ophthalmol"},{"key":"BFeye2009307_CR34","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/sj.eye.6701375","volume":"18","author":"WC Stewart","year":"2004","unstructured":"Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN . Efficacy and safety of the latanoprost\/timolol maleate fixed combination vs the concomitant brimonidine and latanoprost therapy. Eye 2004; 18: 990\u2013995.","journal-title":"Eye"},{"key":"BFeye2009307_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ophtha.2005.06.027","volume":"113","author":"M Diestelhorst","year":"2006","unstructured":"Diestelhorst M, Larsson LI, European\u2013Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006; 113: 70\u201376.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0161-6420(03)00404-4","volume":"110","author":"AG Konstas","year":"2003","unstructured":"Konstas AG, Papapanos P, Tersis I, Houliara D, Stewart WC . Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005% versus timolol and dorzolamide fixed combination. Ophthalmology 2003; 110: 1357\u20131360.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/archopht.121.4.453","volume":"121","author":"N Orzalesi","year":"2003","unstructured":"Orzalesi N, Rossetti L, Bottoli A, Fumagalli E, Fogagnolo P . The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 2003; 121: 453\u2013457.","journal-title":"Arch Ophthalmol"},{"key":"BFeye2009307_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1046\/j.1600-0420.2004.0205.x","volume":"82","author":"RD Fechtner","year":"2004","unstructured":"Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA, COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%\/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004; 82: 42\u201348.","journal-title":"Acta Ophthalmol Scand"},{"key":"BFeye2009307_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ophtha.2007.03.007","volume":"115","author":"AG Konstas","year":"2008","unstructured":"Konstas AG, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC . Comparison of the 24-hour intraocular pressure-lowering effects of latanoprost and dorzolamide\/timolol fixed combination after 2 and 6 months of treatment. Ophthalmology 2008; 115: 99\u2013103.","journal-title":"Ophthalmology"},{"key":"BFeye2009307_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0002-9394(02)01699-9","volume":"134","author":"PJ Lama","year":"2002","unstructured":"Lama PJ . Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol 2002; 134: 749\u2013760.","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"BFeye2009307_CR41","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S0039-6257(03)00003-1","volume":"48","author":"RF Brubaker","year":"2003","unstructured":"Brubaker RF . Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003; 48 (Suppl 1): S17\u2013S20.","journal-title":"Surv Ophthalmol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/eye2009307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2009307","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/eye2009307.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:09:47Z","timestamp":1684429787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye2009307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,18]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["BFeye2009307"],"URL":"https:\/\/doi.org\/10.1038\/eye.2009.307","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2009,12,18]]}}}